Astra Signs Obesity Drug Deal in China Worth Up to $18.5 Billion
AstraZeneca agreed to pay Chinese company CSPC Pharmaceutical Group Ltd. as much as $18.5 billion for its obesity drug candidates, as the UK drugmaker tries to push into the growing weight-loss market.











